Observational Study of Elizaria® in aHUS Patients
Observational Study of Elizaria® in aHUS Patients
It is a multicenter observational non-comparative study of the efficacy and safety of
 long-term pathogenetic Elizaria® therapy in patients with atypical Hemolytic Uremic Syndrome
After screening, patients meeting all of the inclusion / non-inclusion criteria and
 vaccinated against meningococcal infections were treated by Elizaria®.

 The study is planned to include at least 50 patients receiving Elizaria® for the aHUS
 treatment.

 The study will consist of a screening period of up to 4 weeks, including, if necessary,
 immunization with meningococcal vaccine, a treatment period of 52 weeks.

 Medication will be prescribed in accordance with routine medical practice. Accordingly to
 minimize the risks and subjectivity of assessments the methods adopted in the routine
 practice of treating patients with aHUS will be used.

 Investigators enroll patients with aHUS diagnosis who have indications for pathogenetic
 therapy and who are receiving Elizaria® under the government program. Patients will receive
 medication in accordance with the established requirements of national standards and
 protocols for the treatment of patients with aHUS. The registration of the amount of the drug
 used will be carried out on the basis of information in the Patient Diaries, as well as
 primary documentation.
Inclusion Criteria

 1. Written informed consent to study participation.

 2. Male and female patients aged 2 months and older with documented atypical hemolytic
 uremic syndrome (aHUS)diagnosis.

 3. By the time of inclusion in the study, Elizaria® should be prescribed as a
 pathogenetic therapy for aHUS; Exclusion Criteria

 1. Intolerance to eculizumab, or other components of the drug.